干扰素γ释放试验与结核菌素皮肤试验预测活动性结核的前瞻性队列研究
IGRA或BCG分层TST策略最适合筛查疾病进展风险,但TST-5检出进展者比例最高(83%)。
要点
- T-SPOT.TB、TST-15和QuantiFERON阳性对进展的预测显著优于TST-10和TST-5。
- TST-5检出进展者比例最高(83%),但特异性较低。
核心结论
- 基于IGRA或BCG分层TST的策略最适合高危人群筛查活动性结核进展风险。
- 需进一步评估各国筛查试验的成本效益,并开发廉价无毒治疗以覆盖更多潜在风险人群。
研究设计与样本
- 纳入标准:≥16岁,近期接触活动性结核或5年内从高负担国家移民/频繁旅行者;排除现患结核及因本研究阳性结果接受潜伏结核治疗者。
- 每名参与者接受QuantiFERON-TB Gold-In Tube、T-SPOT.TB和Mantoux TST三种检测,TST采用5mm、10mm及BCG分层阈值(>5mm未接种或15mm接种)判读。
主要发现
- TST-5检出进展者比例最高(64/77,83%),高于其他所有试验和阈值(≤75%)。
关键数值与推荐
- TST阳性阈值:5mm(TST-5)、10mm(TST-10)、BCG未接种>5mm或接种者15mm(TST-15)。
临床怎么用
- 高危人群(近期接触者或高负担国家移民)筛查潜伏结核时,优先采用IGRA或BCG分层TST策略预测活动性结核进展风险。
- TST-5虽检出进展者比例最高,但阳性预测值较低,需结合其他试验和临床评估。
- 阴性结果者年发病率低,可据此调整随访强度。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tackling tuberculosis requires testing and treatment of latent tuberculosis in high-risk groups. The aim of this study was to estimate the predictive values of the tuberculin skin test (TST) and two interferon-γ release assays (IGRAs) for the development of active tuberculosis in high-risk groups-ie, people in recent contact with active tuberculosis cases and from high-burden countries. METHOD: In this prospective cohort study, we recruited participants from 54 centres (eg, clinics, community settings) in London, Birmingham, and Leicester in the UK. Participants were eligible if they were aged 16 years or older and at high risk for latent tuberculosis infection (ie, recent contact with someone with active tuberculosis [contacts] or a migrant who had arrived in the UK in the past 5 years from-or who frequently travelled to-a country with a high burden of tuberculosis [migrants]). Exclusion criteria included prevalent cases of tuberculosis, and participants who were treated for latent tuberculosis after a positive test result in this study. Each participant received three tests (QuantiFERON-TB Gold-In Tube, T-SPOT.TB, and a Mantoux TST). A positive TST result was reported using three thresholds: 5 mm (TST-5), 10 mm (TST-10), and greater than 5 mm in BCG-naive or 15 mm in BCG-vaccinated (TST-15) participants. Participants were followed up from recruitment to development of tuberculosis or censoring. Incident tuberculosis cases were identified by national tuberculosis databases, telephone interview, and review of medical notes. Our primary objective was to estimate the prognostic value of IGRAs compared with TST, assessed by the ratio of incidence rate ratios and predictive values for tuberculosis development. The study was registered with ClinicalTrials.gov, NCT01162265, and is now complete. FINDINGS: Between May 4, 2010, and June 1, 2015, 10 045 people were recruited, of whom 9610 were eligible for inclusion. Of this cohort, 4861 (50·6%) were contacts and 4749 (49·4%) were migrants. Participants were followed up for a median of 2·9 years (range 21 days to 5·9 years). 97 (1·0%) of 9610 participants developed active tuberculosis (77 [1·2%] of 6380 with results for all three tests). In all tests, annual incidence of tuberculosis was very low in those who tested negatively (ranging from 1·2 per 1000 person-years, 95% CI 0·6-2·0 for TST-5 to 1·9 per 1000 person-years, 95% CI 1·3-2·7, for QuantiFERON-TB Gold In-Tube). Annual incidence in participants who tested positively were highest for T-SPOT.TB (13·2 per 1000 person-years, 95% CI 9·9-17·4), TST-15 (11·1 per 1000 person-years, 8·3-14·6), and QuantiFERON-TB Gold In-Tube (10·1 per 1000 person-years, 7·4-13·4). Positive results for these tests were significantly better predictors of progression than TST-10 and TST-5 (eg, ratio of test positivity rates in those progressing to tuberculosis compared with those not progressing T-SPOT.TB vs TST-5: 1·99, 95% CI 1·68-2·34; p<0·0001). However, TST-5 identified a higher proportion of participants who progressed to active tuberculosis (64 [83%] of 77 tested) than all other tests and TST thresholds (≤75%). INTERPRETATION: IGRA-based or BCG-stratified TST strategies appear most suited to screening for potential disease progression among high-risk groups. Further work will be needed to assess country-specific cost-effectiveness of each screening test, and in the absence of highly specific diagnostic tests, cheap non-toxic treatments need to be developed that could be given to larger groups of people at potential risk. FUNDING: National Institute for Health Research Health Technology Assessment Programme 08-68-01.
引用
- Abubakar I, Drobniewski F, Southern J, et al. Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infect Dis. 2018. PMID: 30174209. doi:10.1016/S1473-3099(18)30355-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。